Last year, Roche group revenue edged 1% higher to 63.3 billion Swiss francs, the company reported, beating market expectations of 63.2 billion francs, while core operating profit gained 1% to 22.2 billion Swiss francs, just shy of the average analyst estimate of 22.4 billion francs.
As a result, the stock has fallen about 11% over the past three years, lagging its key global rivals.The onus to reinvigorate the pipeline will be on chief executive officer-designate Thomas Schinecker, who was previously Roche's head of diagnostics and due to be promoted to group CEO in March. Family-controlled Roche said on Thursday that Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, would succeed Anderson.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: